Abstract:Anaplastic large-cell lymphoma (ALCL) can be further classified into anaplastic lymphoma kinase-positive (ALK+) and ALK-negative types. ALK-negative ALCL is indistinguishable from ALK+ ALCL by morphology, but lacks ALK translocation or protein expression. Patients with ALK+ ALCL have an overall better prognosis than patients with ALK-negative ALCL, in part because they are younger, but also likely due to biological factors because ALK-negative ALCL is a molecularly heterogeneous entity.1, 2 MYC is altered in many malignancies including lymphomas and some solid tumours.3 Although the role of MYC dysregulation has been studied extensively in B-cell lymphomas,4-8 studies of MYC aberrations in T-cell lymphomas are very limited. A few reports suggest that T-cell lymphomas often have increased MYC copy number, but rarely carry MYC rearrangement (MYC-R).9-12 To date, only three cases of T-cell lymphoma harbouring MYC-R have been reported in the literature. All three cases were ALK+ ALCL and these neoplasms arose in children who had an aggressive clinical course.13-15 The presence or importance of MYC-R in ALK-negative ALCL has not been reported. Here, we describe two patients with MYC-R ALK-negative ALCL, one of whom also had concurrent dual specificity phosphatase 22 (DUSP22) rearrangement (DUSP22-R). Patient 1, a 58-year-old woman presented to another hospital with a neck mass and B symptoms (fever, night sweats and weight loss). Full blood count (FBC) data were not available. Computerised tomography (CT) showed multiple large lymph nodes involving the cervical, axillary, mediastinal, iliac, inguinal regions and subcutaneous nodules. Excisional biopsy of a neck lymph node revealed ALK-negative ALCL (Fig 1). Using immunohistochemistry and flow cytometry immunophenotyping, the lymphoma cells were positive for CD2, CD3, CD4, CD7 (subset), CD8 (dim), CD30 (uniform and strong), T-cell receptor (TCR) alpha/beta, MYC (10–20%) and were negative for ALK, CD5, CD25, TCR gamma/delta and epithelial membrane antigen (EMA). Proliferation Index by Ki67 was ~80%. Fluorescence in situ hybridisation (FISH) analysis revealed MYC-R. Flow cytometric analysis of the peripheral blood showed aberrant T cells, supporting involvement by lymphoma. Polymerase chain reaction (PCR) analysis of the peripheral blood showed monoclonal T-cell receptor beta (TRB) and T-cell receptor gamma (TRG) rearrangements. Bone marrow examination was negative for lymphoma. The patient was diagnosed with Stage IV ALK-negative ALCL, in leukaemic phase. She received two cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy with partial response, but her lymphoma soon progressed. The patient was transferred to our hospital for further treatment. Re-staging evaluation showed leucocytosis (white blood cell [WBC] count 12·0 × 109/l), anaemia (haemoglobin 97 g/l), normal platelet count (316 × 109/l) and a markedly increased serum lactate dehydrogenase (LDH) level (1112 iu/l). Serology testing for human T-cell leukaemia virus (HTLV) I/II was negative. Blood and bone marrow were positive for lymphoma by morphology and flow cytometry immunophenotyping. Positron emission tomography (PET)/CT revealed bilateral fluorodeoxyglucose-avid lymphadenopathy in the cervical and inguinal regions. She was treated with etoposide, methylprednisolone, high-dose cytarabine and cisplatin (ESHAP) for three cycles. Although a rapid initial response was achieved, her disease progressed again with widespread disease involving the spine, nasopharynx, mid skull base, calvarium and skin. Cerebrospinal fluid examination showed lymphoma cells by morphology and flow cytometry immunophenotypic analysis (Fig 1). The patient’s condition deteriorated rapidly with marked leucocytosis (WBC count 28·8 × 109/l with 82% lymphoma cells) and a markedly increased serum LDH level (14 313 iu/l). She died from disease at 9 months after initial diagnosis. Patient 2, a 63-year-old man presented to another hospital with persistent right leg pain and an inguinal mass. His FBC was normal: WBC count 5·8 × 109/l, haemoglobin 132 g/l and platelet count 180 × 109/l. He did not have any B symptoms. Excisional biopsy of an inguinal lymph node showed ALK-negative ALCL (Fig 2). By immunohistochemistry and flow cytometry, the lymphoma cells were positive for CD2, CD4 (subset), CD30 (uniform and strong), CD45 and MYC (60%), and were negative for ALK, CD3, CD5, CD7, CD8, CD25 and EMA. The Proliferation index by Ki67 was ~95%. FISH analysis showed increased MYC copy number, MYC-R and DUSP22-R. TCR gene rearrangement was not assessed. Bone marrow examination was negative for lymphoma. He was diagnosed with Stage III ALK-negative ALCL and was treated with CHOP with a partial initial response. However, after six cycles of CHOP, PET/CT showed an increasing standardised uptake value (SUV) in the right external iliac lesion. The patient was transferred to our hospital for further management. Re-staging evaluation showed a normal FBC (WBC count 7·7 × 109/l, haemoglobin 141 g/l and platelets count 189 × 109/l) and mildly increased serum LDH level (656 iu/l). Serology testing for HTLV I/II was not performed. A PET/CT revealed multiple large lymph nodes involving the right external iliac, superficial inguinal and retroperitoneal regions, consistent with disease progression. He was treated with brentuximab vedotin every 3 weeks, and after 11 cycles PET/CT showed no evidence of lymphoma. Subsequently, he underwent autologous stem cell transplant (SCT) in the 12th month after diagnosis and remained in complete remission for 3 years before being lost to follow-up. He died 53 months after initial diagnosis (41 months after SCT). The cause of death is unknown. Studies of MYC aberrations in T-cell lymphomas are very limited. A few reports suggest that T-cell lymphomas often have increased MYC copy number. In a small series of patients with Sezary syndrome, 75% of patients had MYC gains.10 Similarly, gains of the chromosome 8q24 locus are frequent in cases of peripheral T-cell lymphoma not otherwise specified.11 Chromosomal amplification of MYC also has been detected in adult T-cell leukaemia/lymphoma.9 In contrast, MYC-R in T-cell lymphomas is rare. In a study of 108 T- and NK-cell lymphoma cases (including four ALK+ ALCL cases), all neoplasms with MYC expression lacked MYC-R.12 To date, only three T-cell lymphoma cases harbouring MYC-R have been reported in the literature and all of them were children with ALK+ ALCL who had an aggressive clinical course. Monaco et al.15 reported a 13-year-old boy with the small cell variant of ALK+ ALCL whose disease progressed despite multiple regimens of chemotherapy and SCT. The patient developed a terminal leukaemic phase, and died 6 months after initial presentation. Spectral karyotyping showed t(2;5)(p23;q35) and t(3;8)(q26.2;q24) and FISH analysis confirmed MYC-R. Moritake et al.14 reported a 11-year-old girl with ALK+ ALCL (common morphological pattern) bearing t(2;5)(p23;q35) and t(8;17)(q24;q25). She failed various combinations of intensive chemotherapy and died 5 months after diagnosis. Southern blot analysis identified MYC-R in this neoplasm. Lastly, Liang et al.13 reported a 9-year-old boy with ALK+ ALCL (common morphological pattern) whose disease widely relapsed during chemotherapy and required aggressive chemotherapy, total body radiation and SCT. He subsequently remained in complete remission for >1·5 years. Conventional cytogenetic analysis showed t(2;5)(p23;q35) and ins(6;8)(q23;q24q23) and FISH analysis confirmed MYC-R. Whole chromosome painting suggested that a novel rearrangement partner for MYC was located on chromosome 6q. This is the first report of MYC-R in patients with ALK-negative ALCL. Both patients shared some common clinical features. They were elderly, had advanced stage disease at diagnosis and experienced rapid disease progression despite aggressive treatment. However, patient 1 had a more aggressive clinical course: leukaemic phase at diagnosis with B symptoms, widespread disease despite multiple lines of chemotherapy, and death at 9 months after initial diagnosis. Pathologically, both patients showed large anaplastic cells resembling the common pattern of ALK+ ALCL cases. Both neoplasms were positive for CD2 and CD4, and were negative for CD5, CD25 and EMA. Patient 1 differed from patient 2 in being positive for CD3, CD7 (subset) and CD8 (dim). The association between CD8 and CD3 expression in patient 1 is consistent with the results of a recent study in which CD8 expression was associated with higher relapse rate in patients with ALK+ ALCL, but not in patients with ALK-negative ALCL.16 The neoplasms in both patients harboured MYC-R, but a high level of MYC expression was only identified in patient 2. Therefore, as shown by others,12 MYC expression does not seem to correlate with MYC-R in ALK-negative ALCL. As has been shown in patients with diffuse large B-cell lymphoma (DLBCL), the MYC-R partner genes in DLBCL can be either immunoglobulin (IG) or non-IG genes, and the type of partner has prognostic importance.7 It would be of interest to know the partner(s) of MYC in ALCLs. As chromosomal analyses were not performed in the present two patients we report, the chromosomal loci of the MYC partner genes are unknown. In the three children with MYC-R ALK+ ALCL reported in the literature, the partner genes are also unknown, but the involved chromosomal loci were 3q26.2, 17q25 and 6q23.13-15 It seems likely that the gene located on 17q25 is ALK lymphoma oligomerisation partner on chromosome 17 (ALO17), as this gene has been identified in translocations involving MYC in ALK+ ALCL cases. Although both patients we report had aggressive disease, patient 2 had a somewhat better clinical course and longer survival. It is uncertain if the better course of patient 2 is related to the presence of DUSP22-R. DUSP22-R has been shown in up to 30% of ALK-negative ALCL and is absent in ALK+ ALCL.17 The overall survival of patients with DUSP22-R ALK-negative ALCL is reported to be good, similar to that of patients with ALK+ ALCL and superior to that of patients with other types of ALK-negative ALCL. However, some patients with DUSP22-R can present with high-risk clinical features and have an aggressive course, including central nervous system (CNS) relapse.18 In conclusion, we report two patients with ALK-negative ALCL associated with MYC-R. Both patients were elderly and presented with advanced stage. Their disease progressed rapidly during chemotherapy and required aggressive treatment. The authors have disclosed that they have no relationships with, or financial interests in, any commercial companies pertaining to this article. Mahsa Khanlari collected some data and wrote the manuscript; Guilin Tang performed the FISH analysis and edited the manuscript. Suyang Hao and Yun Gong provided some pathology specimens. Roberto N. Miranda and Cameron C. Yin edited the manuscript. Wei Xie collected some data. Shaoying Li, Pei Lin, Swaminathan Iyer and Francisco Vega provided expert opinion. L. Jeffrey Medeiros analysed data, provided expert opinion, and edited the manuscript. Jie Xu analysed the data and wrote the manuscript.

Abstract:Acute myeloid leukaemia (AML) is a group of heterogeneous haematological malignancies caused by various genetic abnormalities, including chromosomal translocations and/or somatic mutations. Genomic sequencing efforts in AML, such as The Cancer Genome Atlas1 (TCGA) and the Beat AML programme,2 have identified an intensive catalogue of somatic mutations and gene fusions contributing to AML development. However, these sequencing-based investigations mainly pay attention to nuclear DNAs. Increasing evidence indicates that the altered energy and metabolic dependency of leukaemia cells is an important mechanism of AML pathogenesis.3, 4 Mitochondrial genomic alterations play critical roles in the reprogramming of mitochondrial metabolism.5, 6 However, the systematic understanding of somatic mitochondrial mutations and their interplay with the nuclear genome in AML remains poorly understood. In this study, we characterized somatic mitochondrial mutations and their interaction with nuclear driver mutations using whole-exome sequencing (WES) and/or RNA-seq data of 375 AML patients from the Beat AML (n = 175) and TCGA (n = 200) cohorts. We first applied an integrated approach (details in the Supporting Information) to call somatic mitochondrial DNA (mtDNA) mutations in 175 AML patients from the Beat AML cohort (mean coverage, ~346× in AML, ~414× in matched controls). A total of 134 somatic mtDNA mutations were identified, which were located in 130 mitochondrial nucleotide positions. A proportion of approximately 61% were located in protein-coding regions, followed by approximately 17% in two ribosomal RNA genes, approximately 14% in D-loop regions and approximately 8% in tRNA genes (Figure 1A). As previously reported, all 134 somatic mutations were heteroplasmic and most of them (~86%) had low variant allele frequency (VAF, <0.2). Notably, there were two heteroplasmic mutations (one in MT-CO3, missense mutation; the another in the D-loop) with a VAF of 0.9 or higher, suggesting that these two mutations might alter the cellular functions of AML cells due to the heteroplasmy threshold effect of mitochondria. In addition, the mutational signatures of AML mtDNAs were enriched in transition with A:T > G:C (~46%) and G:C > A:T (~46%) (Figure 1C). Among 82 somatic mtDNA mutations in protein-coding regions, about 68% were missense variants, suggesting that more than two-thirds of mutations could result in the alteration of coded amino acids. The top three mutated genes were MT-ND4, MT-ND5 and MT-CYTB, respectively (Figure 1D). Mutations of these three mitochondrial genes have also been found in solid cancers, such as prostate and lung cancer. Our results provided evidence that somatic mtDNA mutations might contribute to the pathogenesis of AML, consistent with the previous observation that mitochondrial Electron Transport Chain (ETC) gene mutations are negatively associated with clinical outcomes in AML.7 To understand the characterization of the transmission of mitochondrial mutations from DNA to the RNA level, we further used corresponding RNA-seq data to identify the mtDNA mutations at the mRNA level based on 51 AML patients from the Beat AML database with WES data. There were 84 mutations at mtDNAs found in 51 AML patients. Among these 84 mtDNA mutations, approximately 73% (61) of mutations were also found at the mitochondrial RNA level and the frequencies of the majority (~82%, 50 of 61) were consistent between mitochondrial DNA and RNA with less than 5% frequency difference (Figure 1E). The allele frequencies of most (~83% of 24) remaining heteroplasmic mutations that were lost at the mitochondrial RNA level were 0.1 or less, and there were only two mtDNA variants with an allele frequency of 0.25 or above, supporting that heteroplasmic DNA mutations with high allele frequency can be transcribed into mitochondrial RNA with high fidelity. Together, these results indicated the congruence of mutations between mitochondrial DNA and RNA in AML. Next, we performed an integrated analysis to investigate the interplay between mitochondrial and nuclear driver mutations/alterations in AML. As expected, somatic mitochondrial mutations were mutually exclusive with mutations in IDH1 (p < 0.05, Fisher's exact test; Beat AML cohort) (Figure 1F; see Table S1 for the contingency table), which has been reported to contribute to an enhanced mitochondrial oxidative metabolism.8 Notably, we also found that somatic mitochondrial mutations were mutually exclusive to the CBFB::MYH11 fusion gene in the Beat AML cohort (p < 0.05, Fisher's exact test) (Figure 1F; see Table S2 for the contingency table). To validate this finding, we further extracted the genomic data of nuclear and mitochondrial alterations from the TCGA cohort (n = 200). Consistent with the findings from the Beat AML cohort, we found complete mutual exclusivity between mitochondrial mutations and CBFB::MYH11 in the TCGA cohort (Figure 1F; see Table S3 for the contingency table). The mutually exclusive pattern indicated the existence of substitutable functional mutations, which often align with the same biological pathways.9 Therefore, it is deduced that the CBFB::MYH11 fusion gene is probably involved in the metabolism reprogramming associated with mitochondrial metabolism in AML. To validate this assumption, we retrieved differentially expressed genes driven by CBFB::MYH11 using public RNA-seq data on CBFB::MYH11 overexpressed cells versus the parental cells.10 A total of 985 upregulated genes and 1138 downregulated genes were found in CBFB::MYH11 overexpressed cells (Figure 2A). Gene ontology (GO) enrichment analysis showed that the CBFB::MYH11-downregulated genes were expectedly enriched by functional categories associated with neutrophil activation and regulation of cytokine-mediated signalization. Interestingly, we found that the CBFB::MYH11-upregulated genes were mainly enriched with metabolic pathways, that is, lipid, fatty acid and glycosphingolipid metabolic processes (Figure 2B). We then conducted enrichment analysis for metabolic pathways in the KEGG database and found that CBFB::MYH11-upregulated genes, including ABO, FUT1, GBGT1, GLA, ST3GAL3, ST3GAL5 and ST6GALNAC6, contributed to the activation of glycosphingolipid biosynthesis (Figure 2C). This pathway is known to play a compensatory role in mitochondrial dysfunction. This finding on the CBFB::MYH11-overexpressed cell line was further confirmed by two independent cohorts performed on primary AML patients (details in the Supporting Information). As shown in Figure 2D,E, most of the genes involved in glycosphingolipid biosynthesis identified above showed a tendency to be highly expressed in AML patients with CBFB::MYH11 compared to those without this fusion. Among them, mutations in ST3GAL5 have been reported to induce GM3 synthase deficiency and then alter the biosynthesis of glycolipid, and its aberrant expression contributes to mitochondrial dysfunction.11, 12 Given that CBFB::MYH11 is an oncogenic transcription factor, we asked whether the upregulation of these genes involved in the glycosphingolipid biosynthesis is caused by the direct binding of CBFB::MYH11. We then downloaded ChIP-seq data (GSE46044) for CBFB::MYH11 in AML.13 Interestingly, we found that the flanking regions (mainly promoter regions with ≤1 kb of transcription start site [TSS]) of all these seven genes show signal enrichment by CBFB::MYH11 in at least one sample. Particularly, the results showed that the promoter region (≤1 kb of TSS) of ST3GAL5 was enriched in all the ChIP-seq data (Figure 2F), indicating that the increased expression of ST3GAL5 could be directly regulated by the CBFB::MYH11 fusion protein. To validate the activation effect of CBFB::MYH11, we selected ST3GAL5 as the target gene because of its well-known function on mitochondrial dysfunction and the strong enrichment signals on chromatin-based on our analysis of ChIP-seq data. We constructed a CBFB::MYH11-expressing cell model in the haematopoietic cell line U937 (Figure 2G). Indeed, a significantly increased ST3GAL5 expression was detected by the quantitative reverse transcription polymerase chain reaction after the induction of CBFB::MYH11 expression (Figure 2H). Next, to determine whether CBFB::MYH11 transcriptionally activates ST3GAL5 by directly binding to the promoter region, a luciferase reporter assay was performed by transfecting the reporter plasmids containing a 500 bp-long promoter region of ST3GAL5 in U937 cells with and without CBFB::MYH11 overexpression. As shown in Figure 2I, the luciferase activity of the ST3GAL5 promoter was significantly increased in CBFB::MYH11-overexpressing U937 cells (p < 0.05) compared with parental cells. A recent study has shown that CBFB::MYH11 can activate target genes by interacting with RUNX1 on chromatin in abnormal myeloid progenitors.14 We also found a colocalization of CBFB::MYH11 and RUNX1 on the ST3GAL5 promoter region (Figure 2F). We then asked whether RUNX1 is indispensable in the CBFB::MYH11-mediated activation of ST3GAL5. As shown in Figure 2J, we performed RUNX1 knock-down experiments in CBFB::MYH11-expressing U937 cells and found that RUNX1 knock-down led to a significant decrease in ST3GAL5 expression (Figure 2J). Also, a reduced luciferase reporter activity was observed in CBFB::MYH11-expressing U937 cell after RUNX1 knock-down (p < 0.05; Figure 2K), and the consistent result was confirmed in the ME1 cell line carrying the CBFB::MYH11 fusion gene (Figure 2K). Collectively, these experiments suggested that CBFB::MYH11 increased the transactivation of ST3GAL5 to induce the glycosphingolipid pathway in a RUNX1-dependent manner. Taken together, this study established that the somatic mitochondrial mutations were mutually exclusive to the CBFB::MYH11 fusion gene in AML. Further mechanistic investigations showed that CBFB::MYH11 contributed to the activation of glycosphingolipid biosynthesis in a RUNX1-dependent manner by directly activating and binding to genes involved in this pathway. Given that AML patients with IDH1 mutations are mutually exclusive to mitochondrial mutations and maintain sensitivity to venetoclax,15 it should be possible to develop a novel therapeutic strategy by combining it with the mitochondrial metabolism as a target to treat AML patients with the CBFB::MYH11 fusion gene. Kankan Wang supervised the study and analysis; Chaoxian Zhao, Siyang Wang and Kankan Wang analysed the data and conducted experiments; Kankan Wang and Chaoxian Zhao wrote the manuscript; and all authors discussed the results and implications and reviewed the manuscript. This work was supported by the National Natural Science Foundation of China (81890994), the National Key R&D Programme of China (2019YFA0905902) and the Innovative Research Team of High-level Local Universities in Shanghai. The computations were run on the π 2.0 cluster supported by the Center for High Performance Computing at Shanghai Jiao Tong University. All authors declare no competing financial interests. Files containing somatic mitochondrial mutations in AML and the list of differentially expressed genes between CBFB::MYH11 overexpressed cells and the parental cells are available at our GitHub web site (https://github.com/Chaoxian/CBFB::MYH11_mutual_exclusivity). Appendix S1 Table S1 Table S2 Table S3 Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

IDH1R132S‐mutated Acute Lymphoblastic Leukaemia Resembles Burkitt Lymphoma/leukaemia Via Activating MYC

IDH1/2-Mutated B-ALL Presents As Burkitt's Leukemia/Lymphoma-like ALL

Clinical Features, Tumor Biology, and Prognosis Associated with MYC Rearrangement and Myc Overexpression in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-Chop

Patients with Diffuse Large B-cell Lymphoma of Germinal Center Origin with BCL2 Translocations Have Poor Outcome, Irrespective of MYC Status: a Report from an International DLBCL Rituximab-Chop Consortium Program Study.

MYC/BCL2 Protein Coexpression Contributes to the Inferior Survival of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma and Demonstrates High-Risk Gene Expression Signatures: a Report from the International DLBCL Rituximab-CHOP Consortium Program.

A Novel MYC–non‐IG Fusion in Refractory Diffuse Large B‐cell Lymphoma

Relapse with BCR-ABL1 Elevation in Chronic Myeloid Leukemia after Progression to Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance with a Persistent KMT2D Mutation

Anaplastic Lymphoma Kinase (alk)‐negative Anaplastic Large Cell Lymphoma with MYC Rearrangement

Characterization of Cases with the Rare Cytogenetic Abnormality I(7)(p10) Reveals an Association with IDH2 Mutated Acute Myeloid Leukemia

MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma

SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia

MYC -rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Single Cell Transcriptomic Profiling of Patient-Derived Xenografts of Mantle Cell Lymphoma Reveals a Special Tumor Cell Population: Seed Cells for Disease Dissemination and Progression

Mutual Exclusivity Between the Fusion Gene CBFB::MYH11 and Somatic Mitochondrial Mutations in Acute Myeloid Leukaemia

Mutational Profiles during the Progression of Chronic Myeloid Leukemia

Identification of Clinical Molecular Targets for Childhood Burkitt Lymphoma.

Expression Level of P-Stat5, C-Myc and IKZF1 by Immunohistochemistry Might Correlate with Adverse Clinic Outcome in Adult B- Lymphoblastic Leukemia (B-ALL)

The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project

A Novel SLC1A1‐RIC1 Fusion Sensitive to Asparaginase‐based Therapy in Natural Killer/t‐cell Lymphoma

Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study